alexa The World must Seriously Consider with Urgency the Use of Thioridazine in Combination with Conventional Antibiotics for Therapy of Extensively Drug Resistant Pulmonary Tuberculosis: Therapy Proven Effective in Argentina | Open Access Journals
ISSN: 2161-1068
Mycobacterial Diseases
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

The World must Seriously Consider with Urgency the Use of Thioridazine in Combination with Conventional Antibiotics for Therapy of Extensively Drug Resistant Pulmonary Tuberculosis: Therapy Proven Effective in Argentina

Leonard Amaral*

Institute of Hygiene and Tropical Medicine, Universidade Nova de Lisboa, Lisbon, Portugal

Corresponding Author:
Leonard Amaral
Travel Medicine of the CMDT
Institute of Hygiene and Tropical Medicine
Universidade Nova de Lisboa, Lisbon, Portugal
E-mail: [email protected]

Received Date: October 31, 2013; Accepted Date: November 08, 2014; Published Date: November 18, 2014

Citation: Amaral L (2014) The World must Seriously Consider with Urgency the Use of Thioridazine in Combination with Conventional Antibiotics for Therapy of Extensively Drug Resistant Pulmonary Tuberculosis: Therapy Proven Effective in Argentina. Mycobact Dis 4:e130. doi:10.4172/2161-1068.1000e130

Copyright: © 2014 Amaral L. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Mycobacterial Diseases

Editorial

During the 1950’s, the consensus among infection disease practitioners was that pulmonary tuberculosis, as a consequence of the effectiveness of the two main anti-tuberculosis drugs, isoniazid (INH) and rifampicin (RIF), would soon be globally eradicated. However, as a consequence of civil unrest, wars, poverty and famine primarily in third world countries, the incidence of tuberculosis infections increased dramatically in these countries and what was once a curable infection, became frequently resistant to INH and Rif (termed multi-drug resistance tuberculosis (MDR-TB) as a consequence of poor delivery of therapy, ineffective therapy and patient non-compliance. By the late 1980’s, the emergence of HIV/AIDS contributed further to the escalation of TB especially in Western countries and coupled to large numbers of migrants infected with Mycobacterium tuberculosis, the causative pathogen of pulmonary tuberculosis, that settled in the major cities of Western countries and later presented with active tuberculosis, the incidence of pulmonary TB reached critical levels, especially in New York City where the incidence quadrupled and more than half of the isolates of the infecting bacterium exhibited an MDR phenotype. It soon became clear MDR-TB was a dire threat to global health and because MDR-TB produces a high percentage of mortality, the need for effective drugs was urgent. However, for a variety of reasons, the pharmaceutical industry did not respond, and the only anti-TB drugs that were available termed second-line of defence drugs, produced high incidence of morbidity, and for the most part, where support for therapy of TB is poor or non-existent, their effective use was limited due to costs and MDR-TB patients were treated poorly and multi-drug resistance evolved to higher levels of resistance such as extensively drug resistant TB (XDR-TB), and in the last two years, especially in India, resistance progressed to the level where the infective organism was resistant to all known and available anti-TB drugs (TDR-TB). At the time of this writing, with the exception of one agent in combination with anti-TB drugs to which the infective bacterium was initially resistant, there are in effect no drugs that can effectively treat XDR-TB and certainly TDR-TB. It is the purpose of this Editorial to present the proven potential of the old phenothiazine neuroleptic thioridazine (TZ) in combination with commonly available anti-TB drugs for the therapy of XDR and most likely TDR-TB.

TZ has in vitro activity against all encountered Mtb regardless of its antibiotic resistance status [1-3]. However, the activity takes place at concentrations of TZ that well exceed its toxic level in the human. Nevertheless, TZ induces the killing of phagocytosed MDR-Mtb and XDR-Mtb by non-killing macrophages at concentrations which are well within the limits of its toxic range in humans [4-6]. These latter studies were followed by a number of independent studies that demonstrated that TZ can cure the mouse of a pulmonary TB infection either by itself as monotherapy or in combination with antibiotics [7-9]. Finally, TZ when used in combination with antibiotics to which the initial infective XDR-Mtb strain was resistant, 17 XDR-TB patients were cured [10,11]. TZ has also been used as a salvage drug for XDR-TB patients, i.e. it improved the quality of life of XDR-TB patients (restored appetite and patients gained weight, obviated night time sweats, and reduced stress associated with a terminal condition) and as has been the case with its use for combinational therapy of XDR-TB, it does not produce any cardiopathology when the patient is properly monitored [12]. These successes demonstrate that TZ has the potential to cure XDR-TB, it is safe to use, it is cheap and must be seriously considered by countries such as India that have a huge XDR-TB load and now present with increasing numbers of TDR-TB cases [13]. The global health community must heed its use for therapy of pulmonary TB infections that are beyond current therapeutic effectiveness.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 11531
  • [From(publication date):
    December-2014 - Oct 21, 2017]
  • Breakdown by view type
  • HTML page views : 7778
  • PDF downloads :3753
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords